Emcure Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Emcutix Biopharmaceuticals, a wholly owned subsidiary of Emcure Pharmaceuticals, announced an exclusive in-licensing agreement with WiQo, an innovative Italian derma-cosmetic and medical device company specialised in scientifically validated products. The strategic partnership grants Emcutix the rights to import, promote, distribute and sell WiQo's ground breaking product PRX-PLUS in India. The collaboration is set to redefine the landscape of non-invasive skin treatments in the region.

PRX-PLUS has a unique product feature with its deep-impacting formula that instantly tightens the skin, offering a non-invasive, pain-free alternative to traditional aesthetic treatments for those seeking effective results with convenience.

Sathya Narayanan, CEO - Emcutix Biopharmaceuticals commented, At Emcutix Biopharmaceuticals, our vision is to bring innovative and high-quality dermatology solutions to the Indian market. Our collaboration with WiQo marks a significant step toward fulfilling this commitment, introducing PRX-PLUS, a unique and advanced skincare solution. With the strong marketing expertise of Emcutix, we are confident that PRX-PLUS will set new benchmarks in dermatological care, making cutting-edge skincare more accessible to consumers across India.

Powered by Capital Market - Live News

Emcure Pharmaceuticals announced its entry into the daily supplements space with the expansion of its Arth range. With a comprehensive approach to holistic well-being, Arth offers a wide range of supplements that harness the power of ancient Indian herbs like Brahmi, with the precision of modern science to address key health concerns that are often overlooked. As an initiative within its broader efforts for quality and women's health education, Emcure has partnered with acclaimed actor and women's health advocate Vidya Balan as the brand ambassador for its Arth range. A respected household name across the nation, Vidya will spark conversations around less discussed and important aspects of health, including inmate care and sleep issues, encouraging women to prioritize and take charge of their health.

As a part of the association, Vidya will spotlight three key products from the Arth range: Inmate Care to soothe itchiness and dryness in inmate areas, Sleep Support Gummies for blissful and quality sleep; Brain Fog Aid to improve focus and support cognition.

Powered by Capital Market - Live News

Emcure Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had conducted a current Good Manufacturing Practices (cGMP) inspection of Company's API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune - 413802, Maharashtra, from 19 February 2025 to 25 February 2025. On conclusion of the inspection, the Company received two observations in Form 483.

Powered by Capital Market - Live News

Emcure Pharmaceuticals announced its entry into the daily supplements space with the expansion of its Arth range. With a comprehensive approach to holistic well-being, Arth offers a wide range of supplements that harness the power of ancient Indian herbs like Brahmi, with the precision of modern science to address key health concerns that are often overlooked. As an initiative within its broader efforts for quality and women's health education, Emcure has partnered with acclaimed actor and women's health advocate Vidya Balan as the brand ambassador for its Arth range. A respected household name across the nation, Vidya will spark conversations around less discussed and important aspects of health, including inmate care and sleep issues, encouraging women to prioritize and take charge of their health.

As a part of the association, Vidya will spotlight three key products from the Arth range: Inmate Care to soothe itchiness and dryness in inmate areas, Sleep Support Gummies for blissful and quality sleep; Brain Fog Aid to improve focus and support cognition.

Powered by Capital Market - Live News

Emcure Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had conducted a current Good Manufacturing Practices (cGMP) inspection of Company's API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune - 413802, Maharashtra, from 19 February 2025 to 25 February 2025. On conclusion of the inspection, the Company received two observations in Form 483.

Powered by Capital Market - Live News

According to an exchange filing, the inspection was conducted at the company’s Active Pharmaceutical Ingredient (API) manufacturing facility located at M.I.D.C., Kurkumbh, Maharashtra, from 19 February 2025 to 25 February 2025. At the conclusion of the inspection, the company received two observations in Form 483.

The company has stated that it is addressing the observations comprehensively and will respond to the USFDA within the required timeframe.

Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.

The company’s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.

The counter rose 0.96% to settle at Rs 988.80 on Tuesday, 25 February 2025. The stock market is closed today on account of Mahashivratri.

Powered by Capital Market - Live News

Emcutix Biopharmaceuticals, a wholly owned subsidiary of Emcure Pharmaceuticals, announced an exclusive in-licensing agreement with WiQo, an innovative Italian derma-cosmetic and medical device company specialised in scientifically validated products. The strategic partnership grants Emcutix the rights to import, promote, distribute and sell WiQo's ground breaking product PRX-PLUS in India. The collaboration is set to redefine the landscape of non-invasive skin treatments in the region.

PRX-PLUS has a unique product feature with its deep-impacting formula that instantly tightens the skin, offering a non-invasive, pain-free alternative to traditional aesthetic treatments for those seeking effective results with convenience.

Sathya Narayanan, CEO - Emcutix Biopharmaceuticals commented, At Emcutix Biopharmaceuticals, our vision is to bring innovative and high-quality dermatology solutions to the Indian market. Our collaboration with WiQo marks a significant step toward fulfilling this commitment, introducing PRX-PLUS, a unique and advanced skincare solution. With the strong marketing expertise of Emcutix, we are confident that PRX-PLUS will set new benchmarks in dermatological care, making cutting-edge skincare more accessible to consumers across India.

Powered by Capital Market - Live News

Emcure Pharmaceuticals announced its entry into the daily supplements space with the expansion of its Arth range. With a comprehensive approach to holistic well-being, Arth offers a wide range of supplements that harness the power of ancient Indian herbs like Brahmi, with the precision of modern science to address key health concerns that are often overlooked. As an initiative within its broader efforts for quality and women's health education, Emcure has partnered with acclaimed actor and women's health advocate Vidya Balan as the brand ambassador for its Arth range. A respected household name across the nation, Vidya will spark conversations around less discussed and important aspects of health, including inmate care and sleep issues, encouraging women to prioritize and take charge of their health.

As a part of the association, Vidya will spotlight three key products from the Arth range: Inmate Care to soothe itchiness and dryness in inmate areas, Sleep Support Gummies for blissful and quality sleep; Brain Fog Aid to improve focus and support cognition.

Powered by Capital Market - Live News

Emcure Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had conducted a current Good Manufacturing Practices (cGMP) inspection of Company's API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune - 413802, Maharashtra, from 19 February 2025 to 25 February 2025. On conclusion of the inspection, the Company received two observations in Form 483.

Powered by Capital Market - Live News

Emcure Pharmaceuticals announced its entry into the daily supplements space with the expansion of its Arth range. With a comprehensive approach to holistic well-being, Arth offers a wide range of supplements that harness the power of ancient Indian herbs like Brahmi, with the precision of modern science to address key health concerns that are often overlooked. As an initiative within its broader efforts for quality and women's health education, Emcure has partnered with acclaimed actor and women's health advocate Vidya Balan as the brand ambassador for its Arth range. A respected household name across the nation, Vidya will spark conversations around less discussed and important aspects of health, including inmate care and sleep issues, encouraging women to prioritize and take charge of their health.

As a part of the association, Vidya will spotlight three key products from the Arth range: Inmate Care to soothe itchiness and dryness in inmate areas, Sleep Support Gummies for blissful and quality sleep; Brain Fog Aid to improve focus and support cognition.

Powered by Capital Market - Live News

Emcure Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had conducted a current Good Manufacturing Practices (cGMP) inspection of Company's API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune - 413802, Maharashtra, from 19 February 2025 to 25 February 2025. On conclusion of the inspection, the Company received two observations in Form 483.

Powered by Capital Market - Live News

According to an exchange filing, the inspection was conducted at the company’s Active Pharmaceutical Ingredient (API) manufacturing facility located at M.I.D.C., Kurkumbh, Maharashtra, from 19 February 2025 to 25 February 2025. At the conclusion of the inspection, the company received two observations in Form 483.

The company has stated that it is addressing the observations comprehensively and will respond to the USFDA within the required timeframe.

Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.

The company’s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.

The counter rose 0.96% to settle at Rs 988.80 on Tuesday, 25 February 2025. The stock market is closed today on account of Mahashivratri.

Powered by Capital Market - Live News